BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Gets Price Target Cut from Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective cut by Morgan Stanley from $122.00 to $119.00 in a research report released on Tuesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Citigroup upped their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Cantor Fitzgerald restated an “overweight” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday. Raymond James Financial raised BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price target on the stock in a research report on Monday, October 12th. Weiss Ratings cut BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. Finally, Oppenheimer cut their price objective on BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating for the company in a report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.91.

BioMarin Pharmaceutical Stock Down 1.7%

BMRN stock opened at $56.15 on Tuesday. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.44 and a quick ratio of 1.32. The business has a 50-day moving average of $59.87 and a 200-day moving average of $58.47. The stock has a market capitalization of $10.88 billion, a P/E ratio of 32.10, a P/E/G ratio of 0.68 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.28. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The company’s quarterly revenue was up 32.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.12 EPS. On average, sell-side analysts anticipate that BioMarin Pharmaceutical will post 2.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust increased its stake in BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after buying an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $39,000. Keating Financial Advisory Services Inc. bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at approximately $56,000. Root Financial Partners LLC bought a new stake in BioMarin Pharmaceutical in the third quarter worth $88,000. Finally, Parallel Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 33.9% in the 1st quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 448 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported Q3 revenue of $1.02 billion, up 32% year over year, and EPS of $0.23 versus analysts’ expected loss of $0.05. Revenue was in line with consensus, while earnings beat expectations. BioMarin Q3 2026 earnings call highlights
• Positive Sentiment: An analyst sees a more attractive risk-reward profile ahead of three FDA decisions. Potential expansion of Voxzogo into hypochondroplasia and revenue from the Amicus acquisition could support growth, though the acquisition’s debt burden remains a consideration. BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
• Neutral Sentiment: JPMorgan lowered its price target to $86 from $87 but maintained an Overweight rating. HC Wainwright also reaffirmed its Neutral rating. JPMorgan analyst rating HC Wainwright rating
• Neutral Sentiment: Management plans to present at three November investor conferences; the announcement did not include new financial guidance. BioMarin investor conferences announcement
• Negative Sentiment: Royal Bank of Canada and Morgan Stanley lowered their expectations for BMRN, contributing to selling pressure and a gap lower in the shares following an analyst downgrade. RBC lowers expectations Morgan Stanley lowers expectations Shares gap down following analyst downgrade

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.